Utilize este identificador para referenciar este registo:
https://hdl.handle.net/1822/82536
Registo completo
Campo DC | Valor | Idioma |
---|---|---|
dc.contributor.author | Afonso, Julieta | por |
dc.contributor.author | Gonçalves, Céline | por |
dc.contributor.author | Costa, Marta | por |
dc.contributor.author | Ferreira, Débora Carina Gonçalves Abreu | por |
dc.contributor.author | Santos, Lúcio | por |
dc.contributor.author | Longatto-Filho, Adhemar | por |
dc.contributor.author | Baltazar, Fátima | por |
dc.date.accessioned | 2023-02-07T09:23:32Z | - |
dc.date.available | 2023-02-07T09:23:32Z | - |
dc.date.issued | 2023-01 | - |
dc.identifier.citation | Afonso, Julieta; Gonçalves, Céline; Costa, Marta; Ferreira, Débora; Santos, Lúcio; Longatto-Filho, Adhemar; Baltazar, Fátima, Glucose metabolism reprogramming in bladder cancer: hexokinase 2 (HK2) as prognostic biomarker and target for bladder cancer therapy. Cancers, 15(3), 982, 2023 | por |
dc.identifier.issn | 2072-6694 | por |
dc.identifier.uri | https://hdl.handle.net/1822/82536 | - |
dc.description.abstract | Proliferating cancer cells are able to reprogram their energy metabolism, favouring glycolysis even in the presence of oxygen and fully functioning mitochondria. Research is needed to validate the glycolysis-related proteins as prognostic/predictive biomarkers in urothelial bladder carcinoma (UBC), a malignancy tagged by high recurrence rates and poor response to chemotherapy. Here, we assessed GLUT1, HK2, PFKL, PKM2, phospho-PDH, and LDHA immunoexpression in 76 UBC samples, differentiating among urothelial, fibroblast, and endothelial cells and among normoxic versus hypoxic areas. We additionally studied the functional effects of the HK2 inhibitor 2-deoxy-D-glucose (2DG) in “in vitro” and “in vivo” preclinical UBC models. We showed that the expression of the glycolysis-related proteins is associated with UBC aggressiveness and poor prognosis. HK2 remained as an independent prognostic factor for disease-free and overall survival. 2DG decreased the UBC cell’s viability, proliferation, migration, and invasion; the inhibition of cell cycle progression and apoptosis occurrence was also verified. A significant reduction in tumour growth and blood vessel formation upon 2DG treatment was observed in the chick chorioallantoic membrane assay. 2DG potentiated the cisplatin-induced inhibition of cell viability in a cisplatin-resistant subline. This study highlights HK2 as a prognostic biomarker for UBC patients and demonstrates the potential benefits of using 2DG as a glycolysis inhibitor. Future studies should focus on integrating 2DG into chemotherapy design, as an attempt to overcome cisplatin resistance. | por |
dc.description.sponsorship | The work presented herein was performed at the Life and Health Sciences Research Institute (ICVS), University of Minho. Financial support was provided by the Scientific Microscopy Platform of ICVS, member of the national infrastructure PPBI—Portuguese Platform of Bioimaging (PPBI-POCI-01-0145-FEDER-022122), by National funds, through the Foundation for Science and Technology (FCT)—project UIDB/50026/2020 and UIDP/50026/2020, and by the projects NORTE 01-0145-FEDER-000039 and NORTE-01-0145-FEDER-000055, supported by Norte Portugal Regional Operational Programme (NORTE 2020), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (ERDF). J.A. was supported by FCT (fellowship ref. SFRH/BPD/116784/2016). C.G. was supported by Programme NORTE 2020 [CTTI-117/21-ICVS(1)] and FCT (contract ref. 2021.02600.CEECIND). D.F. was supported by “Liga Portuguesa contra o Cancro—Núcleo Regional do Norte” (fellowship ref. LPCC-NRN). | por |
dc.language.iso | eng | por |
dc.publisher | Multidisciplinary Digital Publishing Institute (MDPI) | por |
dc.relation | PPBI-POCI-01-0145-FEDER-022122 | por |
dc.relation | info:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDB%2F50026%2F2020/PT | por |
dc.relation | info:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDP%2F50026%2F2020/PT | por |
dc.relation | NORTE-01-0145-FEDER-000039 | por |
dc.relation | NORTE-01-0145-FEDER-000055 | por |
dc.relation | info:eu-repo/grantAgreement/FCT/POR_NORTE/SFRH%2FBPD%2F116784%2F2016/PT | por |
dc.relation | 2021.02600.CEECIND | por |
dc.rights | openAccess | por |
dc.subject | Warburg effect | por |
dc.subject | Glycolysis | por |
dc.subject | Hexokinase 2 | por |
dc.subject | 2-deoxy-D-glucose | por |
dc.subject | Urothelial bladder carcinoma | por |
dc.subject | Cisplatin resistance | por |
dc.title | Glucose metabolism reprogramming in bladder cancer: hexokinase 2 (HK2) as prognostic biomarker and target for bladder cancer therapy | por |
dc.type | article | - |
dc.peerreviewed | yes | por |
dc.relation.publisherversion | https://www.mdpi.com/2072-6694/15/3/982/html | por |
dc.comments | CEB56063 | por |
oaire.citationStartPage | 982 | por |
oaire.citationIssue | 3 | por |
oaire.citationConferencePlace | Switzerland | - |
oaire.citationVolume | 15 | por |
dc.date.updated | 2023-02-06T20:32:49Z | - |
dc.identifier.doi | 10.3390/cancers15030982 | por |
dc.description.publicationversion | info:eu-repo/semantics/publishedVersion | - |
dc.subject.wos | Science & Technology | por |
sdum.journal | Cancers | por |
Aparece nas coleções: | CEB - Publicações em Revistas/Séries Internacionais / Publications in International Journals/Series |
Ficheiros deste registo:
Ficheiro | Descrição | Tamanho | Formato | |
---|---|---|---|---|
document_56063_1.pdf | 6,1 MB | Adobe PDF | Ver/Abrir |